This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET)
Drye, Lea T.,
Scherer, Roberta W.,
Lanctôt, Krista L.,
Rosenberg, Paul B.,
Herrmann, Nathan,
Bachman, David,
Mintzer, Jacobo E.
Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes.; Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer […]
The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study
Glasser, Stephen P.,
Wadley, Virginia,
Judd, Suzanne,
Kana, Bhumika,
Prince, Valerie,
Jenny, Nancy,
Kissela, Brett,
Safford, Monika,
Prineas, Ronald,
Howard, George
Background: Statin use and type have been variably associated with impaired or improved cognitive performance.; Hypothesis: To assess the association of statin use and type (lipophilic vs hydrophilic) and cognitive impairment.; Methods: Cross-sectional analysis of 24 595 participants (7191 statin users and 17 404 nonusers) age > or = 45 years, from a population-based national […]
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease
Gillette-Guyonnet, Sophie,
Andrieu, Sandrine,
Dantoine, Thierry,
Dartigues, Jean-François,
Touchon, Jacques,
Vellas, B.
Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]
Acute caffeine administration effect on brain activation patterns in mild cognitive impairment
Haller, Sven,
Montandon, Marie-Louise,
Rodriguez, Cristelle,
Moser, Dominik,
Toma, Simona,
Hofmeister, Jeremy,
Sinanaj, Indrit,
Lovblad, Karl-Olof,
Giannakopoulos, Panteleimon
Previous studies showed that acute caffeine administration enhances task-related brain activation in elderly individuals with preserved cognition. To explore the effects of this widely used agent on cognition and brain activation in early phases of cognitive decline, we performed a double-blinded, placebo-controlled functional magnetic resonance imaging (fMRI) study during an n-back working memory task in […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes
Nakagawa, Kiyotaka,
Kiko, Takehiro,
Miyazawa, Taiki,
Carpentero Burdeos, Gregor,
Kimura, Fumiko,
Satoh, Akira,
Miyazawa, Teruo
Phospholipid hydroperoxides (PLOOH) accumulate abnormally in the erythrocytes of dementia patients, and dietary xanthophylls (polar carotenoids such as astaxanthin) are hypothesised to prevent the accumulation. In the present study, we conducted a randomised, double-blind, placebo-controlled human trial to assess the efficacy of 12-week astaxanthin supplementation (6 or 12 mg/d) on both astaxanthin and PLOOH levels in […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Siemers, Eric R.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon R.,
Farlow, Martin R.,
Paul, Steven M.,
Demattos, Ronald B.
Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]